Authored by: Barbara Straub Williams, Principal, Greg Doggett, Counsel, and Hannah Hauer, Associate
Powers’ Drug Pricing and 340B Program Practice Group
On November 6, 2026, CMS published in the Federal Register the CY 2027 Hospital Outpatient Prospective Payment System (OPPS) final rule (Final Rule). CMS finalized most of its 340B-related proposals as proposed, with two notable changes: a less severe reimbursement reduction for 340B drugs based on HRSA ceiling price data rather than survey data, and a smaller increase to the remedy offset for non-drug items and services.[1]
ASP Minus 28 Percent. CMS finalized a reduction in Medicare payments to hospitals for separately payable 340B drugs from average sales price (ASP)+6% to ASP-28%, effective January 1, 2027. The final cut is smaller than the ASP-33.4% CMS proposed in July, but larger than the ASP-22.5% reduction the U.S. Supreme Court struck down in Am. Hosp. Ass’n v. Becerra, 596 U.S. 724, 739 (2022). Under the Final Rule, drugs acquired outside the 340B Program will continue to be paid at ASP+6%. Despite objections from many commenters, CMS finalized its proposal not to pay an add-on for the overhead and handling costs associated with 340B drugs.
As CMS proposed, the reimbursement cut does not apply to children’s hospitals, PPS-exempt cancer hospitals, rural sole community hospitals, Indian Health Service hospitals, Rural Emergency Hospitals, and critical access hospitals. CMS carved out from the cut vaccines, drugs with transitional pass-through status, and qualifying non-opioid pain management drugs. The reduction applies to off-campus “non-excepted” outpatient departments currently paid at 40% of OPPS rates, even though those departments are paid outside OPPS as a technical matter.
Payment Cut Methodology. Under Section 1833 of the Social Security Act, payment for outpatient drugs that varies by hospital category must equal average acquisition cost “taking into account” survey data. The prior payment cut for 340B drugs weas struck down in Becerra because CMS had not conducted a survey. To remedy this issue, CMS conducted a survey of hospital drug acquisition costs from January 1 to April 7, 2026. In the Final Rule, CMS bases the new payment cut on HRSA 340B ceiling price data while taking the survey data into consideration.
Budget Neutrality. The Medicare statute requires that all changes to OPPS reimbursement be budget neutral. Because the final payment cut is smaller than proposed, the offsetting reimbursement increase to other OPPS reimbursement rates is also smaller. CMS now estimates that payments for 340B drugs will be reduced by approximately $4.65 billion in CY 2027, down from $4.85 billion under the proposed rule. To offset that reduction, CMS will increase payments for other OPPS items and services by approximately 7.5%, compared with 8.44% under the proposed rule. The increase applies to all OPPS hospitals, including those that do not participate in 340B. CMS is not making a budget neutrality adjustment for payment reductions for drugs furnished in non-excepted off-campus departments because those payments are outside OPPS.
2% OPPS Reduction. Since January 1, 2026, CMS has reduced payment for non-drug outpatient items and services by 0.5% to recoup approximately $7.8 billion in increased non-drug payments that hospitals received while the prior 340B payment cut was in effect from 2018 through 2022. CMS finalized a 2% offset effective January 1, 2027. CMS estimates that, at the 2% rate, full recoupment will occur in CY 2031.
Modifier Requirements. Beginning January 1, 2027, hospitals subject to the payment reduction must report modifier JG on claims for 340B-acquired drugs. Modifier TB will be used for pass-through drugs, non-opioid pain management drugs, packaged drugs (status indicator “N”), and 340B-acquired drugs furnished by hospitals exempt from the reimbursement cut. A third modifier, “ND,” must be used to identify drugs acquired outside the 340B program. The CMS chart showing the modifier requirements is reproduced below.
TABLE 76: FINAL DRUG CLAIM MODIFIERS
| Hospital Type | Pass-through Drug (SI”G”) | Separately Payable Drug (SI”K”) | Non-Opioid Treatment for Pain Relief Drug (SI”K1″) | Packaged Drug (SI”N”) |
|---|---|---|---|---|
| 340B Drugs | ||||
| 340B Hospitals, non-excepted and excepted Off Campus PBDs | TB | JG | TB | TB |
| Children’s Hospitals | TB | TB | TB | TB |
| PPS-Exempt Cancer Hospitals | TB | TB | TB | TB |
| Rural Sole Community Hospitals | TB | TB | TB | TB |
| Non-340B Drugs | ||||
| All OPPS Hospitals, non-excepted and excepted Off Campus PBDs | ND | ND Optional | ||
Looking Ahead. Hospital associations or individual hospitals may decide to take legal action against the reimbursement cut based on various issues, including whether the survey data was adequate, whether HRSA ceiling price data accurately reflects costs, or CMS’ failure to give a reasoned basis for the reduction. Based on prior case law, hospitals may not sue until after they have presented a claim for payment under the new reduced rate. Therefore, any lawsuit challenging the payment cut will likely not be filed until after January 1, 2027. In the meantime, hospitals should prepare to begin reporting the JG, TB, and ND modifiers.
[1] The remedy offset is an annual reduction in payments for non-drug items and services that CMS uses to recoup the approximately $7.8 billion in increased non-drug payments hospitals received while the prior 340B payment cut was in effect from 2018 through 2022.
↩
Powers will continue to monitor developments. Please contact Powers’ Drug Pricing and 340B Program Team, or your lead Powers attorney, if you have any questions.
Authored By:
About Powers Law
Powers Pyles Sutter & Verville PC (“Powers”) is a DC based law firm with national practices in healthcare, education, government relations, Indian tribal governments, and nonprofit law. Powers attorneys and professionals are nationally known for their extensive expertise in their practice areas and their commitment to client service. For more information, visit www.PowersLaw.com.



